Maven Securities’s Humacyte HUMA Stock Holding History

Maven Securities’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,049,828	Closed	-$1.79M	–	879
2025 Q1	$1.79M	Buy	+1,049,828	New	+$3.94M	0.05%	305
2022 Q1	–	Sell	-200,000	Closed	-$1.45M	–	1033
2021 Q4	$1.45M	Sell	200,000 -300,000	-60%	-$2.97M	0.04%	257
2021 Q3	$5.8M	Hold	500,000	–	–	0.19%	79
2021 Q2	$5.09M	Sell	500,000 -11,400	-2%	-$117K	0.21%	84
2021 Q1	$5.54M	Buy	+511,400	New	+$5.58M	0.25%	79

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Maven Securities's HUMA Position: Q2 2025 in Review

Maven Securities sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 1,049,828 shares — an estimated $1.79M sold.

Maven Securities first reported a position in HUMA in Q1 2021 and held it in 5 quarters. The position peaked at $5.8M in Q3 2021. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

Maven Securities reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
Maven Securities sold 1,049,828 Humacyte shares in Q2 2025, an estimated $1.79M.
Maven Securities first reported a position in Humacyte in Q1 2021 and held it in 5 quarters.
Maven Securities's Humacyte position peaked at $5.8M in Q3 2021.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.